AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
secnidazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiprotozoals and radiosensitizers, metronidazole derivatives | 2427 | 3366-95-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Secnidazole is a 5-nitroimidazole antimicrobial. 5-nitroimidazoles enter the bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis of susceptible isolates.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 40 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 100 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.215 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.871 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 36.224 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.762 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 88.310 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 94.370 | % | High | 1 |
| herg | hERG pIC50 | 3.840 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.021 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.048 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 92.780 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK,ZAP70 | 38 | |||
| kinase-selectivity-class | AXL,CDK9,DYRK1B,GRK2,MAP2K6,MAPK7,PRKDC,TEK,TTK | 9 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.455 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.469 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.010 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 4.966 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 94.480 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.236 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 95.900 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 90.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 933.254 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 15, 2017 | FDA | SYMBIOMIX THERAPEUTICS LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vomiting | 104.28 | 82.51 | 38 | 87 | 788255 | 89840067 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01RA07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
| ATC | P01AB07 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Nitroimidazole derivatives |
| FDA CS | M0014907 | Nitroimidazoles |
| FDA EPC | N0000175435 | Nitroimidazole Antimicrobial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35820 | antiprotozoal drug |
| CHEBI has role | CHEBI:53000 | epitope |
| CHEBI has role | CHEBI:171664 | antiamoebic agent |
Related Drugs by ATC class:
J01RA Combinations of antibacterials 18 drugs
P01AB Nitroimidazole derivatives 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection by Trichomonas | indication | 56335008 | DOID:1947 |
| Giardiasis | indication | 58265007 | DOID:10718 |
| Bacterial vaginosis | indication | 419760006 | DOID:3385 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.13 | acidic |
| pKa2 | 2.74 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10335390 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10335390 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10682338 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10682338 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10849884 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10849884 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10849884 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10849884 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10857133 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 10857133 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000507 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000507 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000507 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000507 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000508 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000508 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000508 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11000508 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11020377 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11020377 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11020377 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11020377 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11324721 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11324721 | Sept. 4, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11324721 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11324721 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11602522 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11602522 | Sept. 4, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11684607 | Sept. 16, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11684607 | Sept. 16, 2035 | TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11684607 | Sept. 16, 2035 | TREATMENT OF TRICHOMONIASIS IN ADULTS |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 11684607 | Sept. 16, 2035 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | 12280037 | Dec. 11, 2041 | TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | Sept. 15, 2022 | NEW CHEMICAL ENTITY |
| 2GM/PACKET | SOLOSEC | EVOFEM INC | N209363 | Sept. 15, 2017 | RX | GRANULE | ORAL | Sept. 15, 2027 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 3-oxoacyl-[acyl-carrier-protein] synthase 3 | Enzyme | IC50 | 4.55 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07353 | KEGG_DRUG |
| 4037208 | VANDF |
| C0074246 | UMLSCUI |
| CHEBI:140628 | CHEBI |
| CHEMBL498847 | ChEMBL_ID |
| DB12834 | DRUGBANK_ID |
| 71815 | PUBCHEM_CID |
| 3506 | INN_ID |
| C016724 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12925 | IUPHAR_LIGAND_ID |
| R3459K699K | UNII |
| 1946693 | RXNORM |
| 23281 | MMSL |
| 262144 | MMSL |
| d06604 | MMSL |
| 005775 | NDDF |
| 713462001 | SNOMEDCT_US |
| 763524000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Solosec | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69751-400 | GRANULE | 2 g | ORAL | NDA | 31 sections |